MedTrace Logo

Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction

NCT07462182 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2026-03-10

No results posted yet for this study

Summary

The local literature lacks comprehensive information regarding the actual incidence of intrauterine growth restriction (IUGR) and oligohydramnios and currently available therapeutic options. Therefore, the current study was planned with the objective to evaluate the impact of enoxaparin therapy compared with standard management on neonatal outcomes in pregnancies complicated by intrauterine growth restriction (IUGR) with oligohydramnios.

Conditions

  • Intrauterine Growth Restriction

Interventions

DRUG

Enoxaparin

Patients will receive standard management plus enoxaparin 40 mg subcutaneously once daily until delivery

OTHER

Standard Management

Patients will continue with standard management alone.

Sponsors & Collaborators

  • Muhammad Aamir Latif

    lead OTHER

Principal Investigators

  • Maimoona Hafeez · Combined Military Hospital Quetta

  • Sidra Iqbal, FCPS · Combined Military Hospital Quetta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-01
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07462182 on ClinicalTrials.gov